Journal
CANCERS
Volume 14, Issue 17, Pages -Publisher
MDPI
DOI: 10.3390/cancers14174284
Keywords
adverse events; overall survival; hepatocellular carcinoma; overall survival; progression-free survival
Categories
Ask authors/readers for more resources
This study evaluated the correlation between adverse events and overall survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Liver injuries were found to have a negative impact on survival. Fatigue, liver injury, and albumin-bilirubin grade were identified as factors for discontinuation of treatment. It is important to monitor adverse events closely during atezo/beva treatments.
Simple Summary This study aimed to evaluate the correlation between adverse events (AEs) and overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo/beva). Liver injuries were significantly correlated with shorter survival. In a logistic regression analysis, fatigue >= grade 2, liver injury >= grade 3, and modified albumin-bilirubin grade 2b were identified as independent factors for discontinuation due to AEs. We concluded that the development of liver injury was a negative factor for OS and that we should be vigilant in monitoring AE during atezo/beva treatments. This study aimed to evaluate the correlation between adverse events (AEs) and overall survival (OS) in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab (atezo/beva). This was a multicenter study in which 130 patients were enrolled. Hypertension and skin disorders had a significant correlation with longer survival (median survival time (MST): not reached vs. 14.3 months and not reached vs. 14.8 months, p = 0.001 and p = 0.047, respectively). In contrast, liver injuries were significantly correlated with shorter survival (MST: 14.7 months vs. not reached, p = 0.036), and the median development time was 21 days. In a logistic regression analysis, fatigue >= grade 2, liver injury >= grade 3, and modified albumin-bilirubin grade 2b were identified as independent factors for discontinuation due to AEs. The OS in the no discontinuation due to AE group was significantly longer than that in the discontinuation due to AEs group (MST not reached vs. 11.2 months, p = 0.001). We concluded that the development of liver injury was a negative factor for OS and that we should be vigilant in monitoring AE during atezo/beva treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available